首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2017年 8期乙型肝炎 => 综述 =>原发性胆汁性胆管炎药物治疗的基本..
原发性胆汁性胆管炎药物治疗的基本观念及进展
Pharmacotherapy for primary biliary cholangitis: basic concepts and research advances
文章发布日期:2017年07月07日  来源:  作者:金倩雯,涂传涛  点击次数:899次  下载次数:229次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:原发性胆汁性胆管炎(PBC)是一种原因不明的慢性进行性胆汁淤积性肝病,其特征性表现为高特异性的血清抗线粒体抗体和免疫介导的肝内小胆管非化脓性破坏性炎症,从而导致汇管区炎症与纤维化,最终发展为肝硬化及肝衰竭。熊去氧胆酸(UDCA)是目前唯一公认的用于治疗PBC的药物,推荐剂量为13~15 mg·kg-1·d-1,UDCA治疗获得生化应答患者的生存率可明显改善。然而,大约40%的PBC患者对UDCA治疗无应答,这部分存在疾病进展风险的患者亟急需其他药物治疗。基于近年临床研究资料与指南,总结了目前PBC药物治疗的基本观念及最新进展,并展望正在临床试验的治疗新药,以期为UDCA治疗应答欠佳的PBC患者带来新的希望。
【Abstract】:Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease of unknown etiology characterized by highly specific anti-mitochondrial antibody in serum and immune-mediated non-pyogenic destructive infection in the small intrahepatic bile ducts, which can lead to portal inflammation and fibrosis and finally progress to liver cirrhosis and liver failure. At present, ursodeoxycholic acid (UDCA) is the only drug approved for the treatment of PBC with a recommended dose of 13-15 mg/kg/day. There are significant improvements in the survival rate of patients achieving biochemical response after UDCA treatment. However, about 40% of PBC patients do not respond to UDCA, and such patients have a risk of disease progression and are in urgent need of other drugs. With reference to recent clinical studies and guidelines, this article summarizes the basic concepts and latest advances in pharmacotherapy for PBC, as well as the perspectives of new drugs in clinical trials, in order to bring new hopes to PBC patients with poor response to UDCA.
【关键字】:肝硬化,胆汁性;胆汁淤积;治疗;熊去氧胆酸;奥贝胆酸;综述
【Key words】:liver cirrhosis, biliary; cholestasis; therapy; ursodeoxycholic acid; obeticholic acid; review
【引证本文】:金倩雯, 涂传涛. 原发性胆汁性胆管炎药物治疗的基本观念及进展[J]. 临床肝胆病杂志, 2017, 33(8): 1589-1594.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号